

Jubilant Biosys (BVI) Limited
Balance Sheet as at 31 March 2019

		USD	INR (In Thousands)	USD	INR (In Thousands)
	Notes	As at 31 March 2019		As at 31 March 2018	
ASSETS					
Non-current assets					
Financial assets					
Investments	1	13,71,501	94,853	13,71,501	89,381
Total non-current assets		13,71,501	94,853	13,71,501	89,381
Current assets					
Financial assets					
Cash and cash equivalents	2	1,306	90	1,306	85
Other current assets	3	1,750	121	3,208	209
Total current assets		3,056	211	4,514	294
Total assets		13,74,557	95,064	13,76,015	89,675
EQUITY AND LIABILITIES					
Equity					
Equity share capital	4	13,97,501	69,846	13,97,501	69,846
Other equity		(41,765)	23,916	(38,162)	18,742
Total equity		13,55,736	93,762	13,59,339	88,588
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	5	18,821	1,302	16,676	1,087
Total current liabilities		18,821	1,302	16,676	1,087
Total liabilities		18,821	1,302	16,676	1,087
Total equity and liabilities		13,74,557	95,064	13,76,015	89,675

Benny Thomas
General Manager - Finance
Place: Noida
Date: 17 May, 2019

Jubilant Biosys (BVI) Limited**Statement of Profit and Loss for the year ended 31 March 2019**

Particulars	Notes	USD	INR (In	USD	INR (In
		For the year ended 31 March 2019	Thousands)	For the year ended 31 March 2018	Thousands)
Expenses					
Other expenses	6	3,603	252	3,340	215
Total expenses		3,603	252	3,340	215
Loss before tax		(3,603)	(252)	(3,340)	(215)
Tax expense		-	-	-	-
Loss after tax		(3,603)	(252)	(3,340)	(215)
<i>Items that will not be reclassified to profit or loss</i>					
Exchange differences on translation of foreign operations			5,426		433
Other comprehensive income for the year, net of		-	5,426	-	433
Total comprehensive income/ (loss) for the year		(3,603)	5,174	(3,340)	218

Benny Thomas**General Manager - Finance****Place: Noida****Date: 17 May, 2019**

Jubilant Biosys (BVI) Limited
Statement of Changes in Equity for the year ended 31st March 2019

			INR (' In Thousands)
a) Equity share capital	Note	No. of shares	Amount
Balance as at 1 April 2017	4	13,97,501	69,846
Changes in equity share capital during the year			-
Balance as at 31 March 2018	4	13,97,501	69,846
Changes in equity share capital during the year			-
Balance as at 31 March 2019	4	13,97,501	69,846

b) Other Equity

	Reserves and surplus				
	Retained earnings		Exchange differences on translation of foreign operations	Total	
	USD	INR (In Thousands)	INR (In Thousands)	USD	INR (In Thousands)
Balance as at 1 April 2017	(34,822)	15,293	3,231	(34,822)	18,524
Loss for the year	(3,340)	(215)	-	(3,340)	(215)
Exchange loss during the year on translation of foreign operations	-	-	433	-	433
Balance as at 31 March 2018	(38,162)	15,078	3,664	(38,162)	18,742
Loss for the year	(3,603)	(252)	-	(3,603)	(252)
Exchange gain during the year on translation of foreign operations	-	-	5,426	-	5,426
Balance as at 31 March 2019	(41,765)	14,826	9,090	(41,765)	23,916

Benny Thomas
General Manager - Finance
Place: Noida
Date: 17 May, 2019

Jubilant Biosys (BVI) Limited
Statement of Cash Flows for the year ended on 31 March 2019

	USD	INR (In Thousands)	USD	INR (In Thousands)
Particulars	For the year ended on 31 March 2019		For the year ended on 31 March 2018	
A. Cash flow from operating activities				
Loss before tax	(3,603)	(252)	(3,340)	(215)
Operating cash flow before working capital changes				
(Increase)/ decrease in other current assets	1,458	101	(112)	(7)
Increase in trade payables	2,145	149	3,452	222
Cash (used in) from operations	-	(1)	-	-
Income tax paid (net of refund)	-	-	-	-
Net cash used in operating activities	-	(1)	-	-
B. Effect of exchange rate changes	-	7		-
Net decrease in cash and cash equivalents (A+B)	-	5	-	-
Add: cash and cash equivalents at the beginning of year	1,306	85	1,306	85
Cash and cash equivalents at the end of the year	1,306	90	1,306	85

Benny Thomas
General Manager - Finance
Place: Noida
Date: 17 May, 2019

Jubilant Biosys (BVI) Limited
Notes to the financial statements for the year ended 31 March 2019

Note 1. Non-current investments

Jubilant Biosys (Singapore) Pte Ltd

1,371,501 (31 March 2018: 1,371,501 equity shares with no par value)

USD	INR (In Thousands)	USD	INR (In Thousands)
As at 31 March 2019		As at 31 March 2018	
13,71,501	94,853	13,71,501	89,381
13,71,501	94,853	13,71,501	89,381

Note 2. Cash and cash equivalents

Balances with banks:

- On current accounts

1,306	90	1,306	85
1,306	90	1,306	85

Note 3. Other current assets

Prepaid expenses

1,750	121	3,208	209
1,750	121	3,208	209

Jubilant Biosys (BVI) Limited
Notes to the financial statements for the year ended 31 March 2019

Note 4: Equity share capital

	USD As at 31 March 2019	INR (In Thousands)	USD As at 31 March 2018	INR (In Thousands)
Issued, subscribed and paid up equity share capital				
1,397,501 (31 March 2018 : 1,397,501 equity of USD 1 each)	13,97,501	69,846	13,97,501	69,846
	13,97,501	69,846	13,97,501	69,846

Movement in equity share capital

	Note	No. of shares	USD	INR (' In Thousands)
Balance as at 1 April 2017	4	13,97,501	13,97,501	69,846
Changes in equity share capital during the year			-	-
Balance as at 31 March 2018	4	13,97,501	13,97,501	69,846
Changes in equity share capital during the year			-	-
Balance as at 31 March 2019	4	13,97,501	13,97,501	69,846

The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

The details of shareholders holding more than 5% shares in the company : -

	As at 31 March 2019		As at 31 March 2018	
	No of shares	% holding in the class	No of shares	% holding in the class
Jubilant Life Sciences (BVI) Limited	13,97,501	100%	13,97,501	100%

Jubilant Biosys (BVI) Limited
Notes to the financial statements for the year ended 31 March 2019

Note 5. Trade payables

Trade payables-others

USD	INR (In Thousands)	USD	INR (In Thousands)
As at 31 March 2019		As at 31 March 2018	
18,821	1,302	16,676	1,087
18,821	1,302	16,676	1,087

Note 6. Other expense

Legal, professional and consultancy charges

3,603	252	3,340	215
3,603	252	3,340	215